Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erinacine A
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
**Erinacine A** is a naturally occurring diterpenoid isolated from the mycelium and fruiting bodies of the medicinal mushroom *Hericium erinaceus* (lion’s mane mushroom)[2][6]. It is best known for its **neuroprotective, neuroregenerative, antidepressant-like, anti-inflammatory, antioxidant, and anti-cancer properties**. Mechanistically, it promotes nerve growth factor (NGF) synthesis and has been shown to activate neurotrophic signaling (BDNF/TrkB/PI3K/Akt/GSK-3β), modulate monoamine neurotransmitter levels (dopamine, serotonin, norepinephrine), inhibit inflammatory mediators (NF-κB, IL-6, TNF-α, iNOS, MAPK), induce antioxidant pathways (Nrf2/HO-1/SOD1), and reduce amyloid-β accumulation associated with neurodegenerative processes[1][3][5][6].
- Other names
- (3aR,5aR,6S)-3a,5a-dimethyl-1-propan-2-yl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,7-hexahydrocyclohepta[e]indene-8-carbaldehydecyathane diterpene(+)-Erinacin A
02
Targets
SERT (Sodium-dependent serotonin transporter)BDNF (Brain-derived neurotrophic factor)GSK3 (Glycogen synthase kinase 3 beta)NOS2 (Nitric Oxide Synthase 2)MEKNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on erinacine A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erinacine A.